APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antibacterial (Drug) Resistance

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Antibacterial (Drug) Resistance Market Outlook and Growth Opportunities 2026

22 December 2025218 pages

Choose your research edition.

Industry ResearchAntibacterial (Drug) Resistance Industry Research Report 2026143 pages · $2,950 USDIndustry Growth & TrendsGlobal Antibacterial (Drug) Resistance Industry Growth and Trends Forecast to 2032123 pages · $3,450 USDMarket StructureGlobal Antibacterial (Drug) Resistance Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antibacterial (Drug) Resistance Market Outlook and Growth Opportunities 2026218 pages · $4,250 USDMarket Analysis & ForecastGlobal Antibacterial (Drug) Resistance Market Analysis and Forecast 2026-2032212 pages · $4,950 USD

Market perspective

The global Antibacterial (Drug) Resistance market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Antibacterial (Drug) Resistance is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Antibacterial (Drug) Resistance is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Antibacterial (Drug) Resistance is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Antibacterial (Drug) Resistance market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Antibacterial (Drug) Resistance market include Merck, Pfizer, GSK, VenatoRx Pharmaceuticals, PENDOPHARM, Osel, Novexel, NanoSafe Coatings and Nabriva Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Antibacterial (Drug) Resistance market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Antibacterial (Drug) Resistance and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Antibacterial (Drug) Resistance sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Antibacterial (Drug) Resistance market size, projected growth trends, production technologies, key applications, and end-use industries.

Antibacterial (Drug) Resistance Segment by Company

Merck

Pfizer

GSK

VenatoRx Pharmaceuticals

PENDOPHARM

Osel

Novexel

NanoSafe Coatings

Nabriva Therapeutics

Morphochem

Microbecide

Melinta Therapeutics

Lyndra

Isis Pharmaceuticals

InterMune

Evolva Holding

Demuris

ContraFect

Cerexa

Aventis Pharma

Austell Laboratories

Assembly Biosciences

Arpida

ANTABIO

Allergan

Acino Holdings

Achaogen

Absynth Biologics

Abbott Laboratories

AAIPharma Services

Antibacterial (Drug) Resistance Segment by Type

Ceftolozane-Tazobactam (Zerbaxa)

Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio)

Ceftaroline Fosamil (Teflaro/ Zinforo)

Ceftazidime-Avibactam (Avycaz/ Zavicefta)

Telavancin (Vibativ)

Tedizolid Phosphate (Sivextro)

PHASE III DRUGS

Dalbavancin (Dalvance/ Xydalba)

Oritavancin (Orbactiv/ Nuvocid)

Fidaxomicin (Dificid / Dificlir)

Antibacterial (Drug) Resistance Segment by Application

Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)

Blood Stream Infections (BSI)

Community Acquired Bacterial Pneumonia (CABP)

Clostridium Difficile Infections (CDI)

Acute Bacterial Skin And Skin Structure Infections (ABSSSI)

Complicated Urinary Tract Infection (CUTI)

Complicated Intra-Abdominal Infections (CIAI)

Antibacterial (Drug) Resistance Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Antibacterial (Drug) Resistance status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Antibacterial (Drug) Resistance market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Antibacterial (Drug) Resistance significant trends, drivers, influence factors in global and regions.

6. To analyze Antibacterial (Drug) Resistance competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antibacterial (Drug) Resistance market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antibacterial (Drug) Resistance and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antibacterial (Drug) Resistance.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Antibacterial (Drug) Resistance market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Antibacterial (Drug) Resistance industry.

Chapter 3: Detailed analysis of Antibacterial (Drug) Resistance manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Antibacterial (Drug) Resistance in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Antibacterial (Drug) Resistance in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Antibacterial (Drug) Resistance Industry Trends Table 2. Antibacterial (Drug) Resistance Industry Drivers Table 3. Antibacterial (Drug) Resistance Industry Opportunities and Challenges Table 4. Antibacterial (Drug) Resistance Industry Restraints Table 5. Global Antibacterial (Drug) Resistance Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Antibacterial (Drug) Resistance Revenue Share by Company (2021-2026) Table 7. Global Antibacterial (Drug) Resistance Sales Volume by Company (k units) & (2021-2026) Table 8. Global Antibacterial (Drug) Resistance Sales Volume Share by Company (2021-2026) Table 9. Global Antibacterial (Drug) Resistance Average Price (US$/unit) of Company (2021-2026) Table 10. Global Antibacterial (Drug) Resistance Company Ranking, (2024-2026) & (USD Million) Table 11. Global Antibacterial (Drug) Resistance Key Company Manufacturing Base & Headquarters Table 12. Global Antibacterial (Drug) Resistance Company, Product Type & Application Table 13. Global Antibacterial (Drug) Resistance Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Antibacterial (Drug) Resistance by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Ceftolozane-Tazobactam (Zerbaxa) Table 18. Significant Companies of Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio) Table 19. Significant Companies of Ceftaroline Fosamil (Teflaro/ Zinforo) Table 20. Significant Companies of Ceftazidime-Avibactam (Avycaz/ Zavicefta) Table 21. Significant Companies of Telavancin (Vibativ) Table 22. Significant Companies of Tedizolid Phosphate (Sivextro) Table 23. Significant Companies of PHASE III DRUGS Table 24. Significant Companies of Dalbavancin (Dalvance/ Xydalba) Table 25. Significant Companies of Oritavancin (Orbactiv/ Nuvocid) Table 26. Significant Companies of Fidaxomicin (Dificid / Dificlir) Table 27. Global Antibacterial (Drug) Resistance Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 28. Global Antibacterial (Drug) Resistance Sales Volume by Type (2021-2026) & (k units) Table 29. Global Antibacterial (Drug) Resistance Sales Volume by Type (2027-2032) & (k units) Table 30. Global Antibacterial (Drug) Resistance Sales Volume Share by Type (2021-2026) Table 31. Global Antibacterial (Drug) Resistance Sales Volume Share by Type (2027-2032) Table 32. Global Antibacterial (Drug) Resistance Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Antibacterial (Drug) Resistance Sales Value by Type (2021-2026) & (US$ Million) Table 34. Global Antibacterial (Drug) Resistance Sales Value by Type (2027-2032) & (US$ Million) Table 35. Global Antibacterial (Drug) Resistance Sales Value Share by Type (2021-2026) Table 36. Global Antibacterial (Drug) Resistance Sales Value Share by Type (2027-2032) Table 37. Significant Companies of Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP) Table 38. Significant Companies of Blood Stream Infections (BSI) Table 39. Significant Companies of Community Acquired Bacterial Pneumonia (CABP) Table 40. Significant Companies of Clostridium Difficile Infections (CDI) Table 41. Significant Companies of Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Table 42. Significant Companies of Complicated Urinary Tract Infection (CUTI) Table 43. Significant Companies of Complicated Intra-Abdominal Infections (CIAI) Table 44. Global Antibacterial (Drug) Resistance Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 45. Global Antibacterial (Drug) Resistance Sales Volume by Application (2021-2026) & (k units) Table 46. Global Antibacterial (Drug) Resistance Sales Volume by Application (2027-2032) & (k units) Table 47. Global Antibacterial (Drug) Resistance Sales Volume Share by Application (2021-2026) Table 48. Global Antibacterial (Drug) Resistance Sales Volume Share by Application (2027-2032) Table 49. Global Antibacterial (Drug) Resistance Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Antibacterial (Drug) Resistance Sales Value by Application (2021-2026) & (US$ Million) Table 51. Global Antibacterial (Drug) Resistance Sales Value by Application (2027-2032) & (US$ Million) Table 52. Global Antibacterial (Drug) Resistance Sales Value Share by Application (2021-2026) Table 53. Global Antibacterial (Drug) Resistance Sales Value Share by Application (2027-2032) Table 54. Global Antibacterial (Drug) Resistance Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 55. Global Antibacterial (Drug) Resistance Sales by Region (2021-2026) & (k units) Table 56. Global Antibacterial (Drug) Resistance Sales Market Share by Region (2021-2026) Table 57. Global Antibacterial (Drug) Resistance Sales by Region (2027-2032) & (k units) Table 58. Global Antibacterial (Drug) Resistance Sales Market Share by Region (2027-2032) Table 59. Global Antibacterial (Drug) Resistance Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Antibacterial (Drug) Resistance Sales Value by Region (2021-2026) & (US$ Million) Table 61. Global Antibacterial (Drug) Resistance Sales Value Share by Region (2021-2026) Table 62. Global Antibacterial (Drug) Resistance Sales Value by Region (2027-2032) & (US$ Million) Table 63. Global Antibacterial (Drug) Resistance Sales Value Share by Region (2027-2032) Table 64. Global Antibacterial (Drug) Resistance Market Average Price (US$/unit) by Region (2021-2026) Table 65. Global Antibacterial (Drug) Resistance Market Average Price (US$/unit) by Region (2027-2032) Table 66. Global Antibacterial (Drug) Resistance Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 67. Global Antibacterial (Drug) Resistance Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 68. Global Antibacterial (Drug) Resistance Sales by Country (2021-2026) & (k units) Table 69. Global Antibacterial (Drug) Resistance Sales Market Share by Country (2021-2026) Table 70. Global Antibacterial (Drug) Resistance Sales by Country (2027-2032) & (k units) Table 71. Global Antibacterial (Drug) Resistance Sales Market Share by Country (2027-2032) Table 72. Global Antibacterial (Drug) Resistance Sales Value by Country (2021-2026) & (US$ Million) Table 73. Global Antibacterial (Drug) Resistance Sales Value Market Share by Country (2021-2026) Table 74. Global Antibacterial (Drug) Resistance Sales Value by Country (2027-2032) & (US$ Million) Table 75. Global Antibacterial (Drug) Resistance Sales Value Market Share by Country (2027-2032) Table 76. Merck Company Information Table 77. Merck Business Overview Table 78. Merck Antibacterial (Drug) Resistance Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 79. Merck Antibacterial (Drug) Resistance Product Portfolio Table 80. Merck Recent Development Table 81. Pfizer Company Information Table 82. Pfizer Business Overview Table 83. Pfizer Antibacterial (Drug) Resistance Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 84. Pfizer Antibacterial (Drug) Resistance Product Portfolio Table 85. Pfizer Recent Development Table 86. GSK Company Information Table 87. GSK Business Overview Table 88. GSK Antibacterial (Drug) Resistance Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 89. GSK Antibacterial (Drug) Resistance Product Portfolio Table 90. GSK Recent Development Table 91. VenatoRx Pharmaceuticals Company Information Table 92. VenatoRx Pharmaceuticals Business Overview Table 93. VenatoRx Pharmaceuticals Antibacterial (Drug) Resistance Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 94. VenatoRx Pharmaceuticals Antibacterial (Drug) Resistance Product Portfolio Table 95. VenatoRx Pharmaceuticals Recent Development Table 96. PENDOPHARM Company Information Table 97. PENDOPHARM Business Overview Table 98. PENDOPHARM Antibacterial (Drug) Resistance Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 99. PENDOPHARM Antibacterial (Drug) Resistance Product Portfolio Table 100. PENDOPHARM Recent Development Table 101. Osel Company Information Table 102. Osel Business Overview Table 103. Osel Antibacterial (Drug) Resistance Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 104. Osel Antibacterial (Drug) Resistance Product Portfolio Table 105. Osel Recent Development Table 106. Novexel Company Information Table 107. Novexel Business Overview Table 108. Novexel Antibacterial (Drug) Resistance Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 109. Novexel Antibacterial (Drug) Resistance Product Portfolio Table 110. Novexel Recent Development Table 111. NanoSafe Coatings Company Information Table 112. NanoSafe Coatings Business Overview Table 113. NanoSafe Coatings Antibacterial (Drug) Resistance Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 114. NanoSafe Coatings Antibacterial (Drug) Resistance Product Portfolio Table 115. NanoSafe Coatings Recent Development Table 116. Nabriva Therapeutics Company Information Table 117. Nabriva Therapeutics Business Overview Table 118. Nabriva Therapeutics Antibacterial (Drug) Resistance Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 119. Nabriva Therapeutics Antibacterial (Drug) Resistance Product Portfolio Table 120. Nabriva Therapeutics Recent Development Table 121. Morphochem Company Information Table 122. Morphochem Business Overview Table 123. Morphochem Antibacterial (Drug) Resistance Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 124. Morphochem Antibacterial (Drug) Resistance Product Portfolio Table 125. Morphochem Recent Development Table 126. Microbecide Company Information Table 127. Microbecide Business Overview Table 128. Microbecide Antibacterial (Drug) Resistance Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 129. Microbecide Antibacterial (Drug) Resistance Product Portfolio Table 130. Microbecide Recent Development Table 131. Melinta Therapeutics Company Information Table 132. Melinta Therapeutics Business Overview Table 133. Melinta Therapeutics Antibacterial (Drug) Resistance Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 134. Melinta Therapeutics Antibacterial (Drug) Resistance Product Portfolio Table 135. Melinta Therapeutics Recent Development Table 136. Lyndra Company Information Table 137. Lyndra Business Overview Table 138. Lyndra Antibacterial (Drug) Resistance Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 139. Lyndra Antibacterial (Drug) Resistance Product Portfolio Table 140. Lyndra Recent Development Table 141. Isis Pharmaceuticals Company Information Table 142. Isis Pharmaceuticals Business Overview Table 143. Isis Pharmaceuticals Antibacterial (Drug) Resistance Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 144. Isis Pharmaceuticals Antibacterial (Drug) Resistance Product Portfolio Table 145. Isis Pharmaceuticals Recent Development Table 146. InterMune Company Information Table 147. InterMune Business Overview Table 148. InterMune Antibacterial (Drug) Resistance Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 149. InterMune Antibacterial (Drug) Resistance Product Portfolio Table 150. InterMune Recent Development Table 151. Evolva Holding Company Information Table 152. Evolva Holding Business Overview Table 153. Evolva Holding Antibacterial (Drug) Resistance Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 154. Evolva Holding Antibacterial (Drug) Resistance Product Portfolio Table 155. Evolva Holding Recent Development Table 156. Demuris Company Information Table 157. Demuris Business Overview Table 158. Demuris Antibacterial (Drug) Resistance Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 159. Demuris Antibacterial (Drug) Resistance Product Portfolio Table 160. Demuris Recent Development Table 161. ContraFect Company Information Table 162. ContraFect Business Overview Table 163. ContraFect Antibacterial (Drug) Resistance Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 164. ContraFect Antibacterial (Drug) Resistance Product Portfolio Table 165. ContraFect Recent Development Table 166. Cerexa Company Information Table 167. Cerexa Business Overview Table 168. Cerexa Antibacterial (Drug) Resistance Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 169. Cerexa Antibacterial (Drug) Resistance Product Portfolio Table 170. Cerexa Recent Development Table 171. Aventis Pharma Company Information Table 172. Aventis Pharma Business Overview Table 173. Aventis Pharma Antibacterial (Drug) Resistance Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 174. Aventis Pharma Antibacterial (Drug) Resistance Product Portfolio Table 175. Aventis Pharma Recent Development Table 176. Austell Laboratories Company Information Table 177. Austell Laboratories Business Overview Table 178. Austell Laboratories Antibacterial (Drug) Resistance Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 179. Austell Laboratories Antibacterial (Drug) Resistance Product Portfolio Table 180. Austell Laboratories Recent Development Table 181. Assembly Biosciences Company Information Table 182. Assembly Biosciences Business Overview Table 183. Assembly Biosciences Antibacterial (Drug) Resistance Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 184. Assembly Biosciences Antibacterial (Drug) Resistance Product Portfolio Table 185. Assembly Biosciences Recent Development Table 186. Arpida Company Information Table 187. Arpida Business Overview Table 188. Arpida Antibacterial (Drug) Resistance Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 189. Arpida Antibacterial (Drug) Resistance Product Portfolio Table 190. Arpida Recent Development Table 191. ANTABIO Company Information Table 192. ANTABIO Business Overview Table 193. ANTABIO Antibacterial (Drug) Resistance Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 194. ANTABIO Antibacterial (Drug) Resistance Product Portfolio Table 195. ANTABIO Recent Development Table 196. Allergan Company Information Table 197. Allergan Business Overview Table 198. Allergan Antibacterial (Drug) Resistance Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 199. Allergan Antibacterial (Drug) Resistance Product Portfolio Table 200. Allergan Recent Development Table 201. Acino Holdings Company Information Table 202. Acino Holdings Business Overview Table 203. Acino Holdings Antibacterial (Drug) Resistance Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 204. Acino Holdings Antibacterial (Drug) Resistance Product Portfolio Table 205. Acino Holdings Recent Development Table 206. Achaogen Company Information Table 207. Achaogen Business Overview Table 208. Achaogen Antibacterial (Drug) Resistance Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 209. Achaogen Antibacterial (Drug) Resistance Product Portfolio Table 210. Achaogen Recent Development Table 211. Absynth Biologics Company Information Table 212. Absynth Biologics Business Overview Table 213. Absynth Biologics Antibacterial (Drug) Resistance Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 214. Absynth Biologics Antibacterial (Drug) Resistance Product Portfolio Table 215. Absynth Biologics Recent Development Table 216. Abbott Laboratories Company Information Table 217. Abbott Laboratories Business Overview Table 218. Abbott Laboratories Antibacterial (Drug) Resistance Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 219. Abbott Laboratories Antibacterial (Drug) Resistance Product Portfolio Table 220. Abbott Laboratories Recent Development Table 221. AAIPharma Services Company Information Table 222. AAIPharma Services Business Overview Table 223. AAIPharma Services Antibacterial (Drug) Resistance Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 224. AAIPharma Services Antibacterial (Drug) Resistance Product Portfolio Table 225. AAIPharma Services Recent Development Table 226. Key Raw Materials Table 227. Raw Materials Key Suppliers Table 228. Antibacterial (Drug) Resistance Distributors List Table 229. Antibacterial (Drug) Resistance Customers List Table 230. Research Programs/Design for This Report Table 231. Authors List of This Report Table 232. Secondary Sources Table 233. Primary Sources List of Figures Figure 1. Antibacterial (Drug) Resistance Product Image Figure 2. Global Antibacterial (Drug) Resistance Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antibacterial (Drug) Resistance Sales Value (2021-2032) & (US$ Million) Figure 4. Global Antibacterial (Drug) Resistance Sales (2021-2032) & (k units) Figure 5. Global Antibacterial (Drug) Resistance Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Antibacterial (Drug) Resistance Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Ceftolozane-Tazobactam (Zerbaxa) Image Figure 10. Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio) Image Figure 11. Ceftaroline Fosamil (Teflaro/ Zinforo) Image Figure 12. Ceftazidime-Avibactam (Avycaz/ Zavicefta) Image Figure 13. Telavancin (Vibativ) Image Figure 14. Tedizolid Phosphate (Sivextro) Image Figure 15. PHASE III DRUGS Image Figure 16. Dalbavancin (Dalvance/ Xydalba) Image Figure 17. Oritavancin (Orbactiv/ Nuvocid) Image Figure 18. Fidaxomicin (Dificid / Dificlir) Image Figure 19. Global Antibacterial (Drug) Resistance Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 20. Global Antibacterial (Drug) Resistance Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Antibacterial (Drug) Resistance Sales Volume Share by Type (2021-2032) Figure 22. Global Antibacterial (Drug) Resistance Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Antibacterial (Drug) Resistance Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Antibacterial (Drug) Resistance Sales Value Share by Type (2021-2032) Figure 25. Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP) Image Figure 26. Blood Stream Infections (BSI) Image Figure 27. Community Acquired Bacterial Pneumonia (CABP) Image Figure 28. Clostridium Difficile Infections (CDI) Image Figure 29. Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Image Figure 30. Complicated Urinary Tract Infection (CUTI) Image Figure 31. Complicated Intra-Abdominal Infections (CIAI) Image Figure 32. Global Antibacterial (Drug) Resistance Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 33. Global Antibacterial (Drug) Resistance Sales Volume Share 2021 VS 2025 VS 2032 Figure 34. Global Antibacterial (Drug) Resistance Sales Volume Share by Application (2021-2032) Figure 35. Global Antibacterial (Drug) Resistance Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 36. Global Antibacterial (Drug) Resistance Sales Value Share 2021 VS 2025 VS 2032 Figure 37. Global Antibacterial (Drug) Resistance Sales Value Share by Application (2021-2032) Figure 38. Global Antibacterial (Drug) Resistance Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 39. Global Antibacterial (Drug) Resistance Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 40. Global Antibacterial (Drug) Resistance Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 41. Global Antibacterial (Drug) Resistance Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 42. North America Antibacterial (Drug) Resistance Sales Value (2021-2032) & (US$ Million) Figure 43. North America Antibacterial (Drug) Resistance Sales Value Share by Country (%), 2025 VS 2032 Figure 44. Europe Antibacterial (Drug) Resistance Sales Value (2021-2032) & (US$ Million) Figure 45. Europe Antibacterial (Drug) Resistance Sales Value Share by Country (%), 2025 VS 2032 Figure 46. Asia-Pacific Antibacterial (Drug) Resistance Sales Value (2021-2032) & (US$ Million) Figure 47. Asia-Pacific Antibacterial (Drug) Resistance Sales Value Share by Country (%), 2025 VS 2032 Figure 48. South America Antibacterial (Drug) Resistance Sales Value (2021-2032) & (US$ Million) Figure 49. South America Antibacterial (Drug) Resistance Sales Value Share by Country (%), 2025 VS 2032 Figure 50. Middle East & Africa Antibacterial (Drug) Resistance Sales Value (2021-2032) & (US$ Million) Figure 51. Middle East & Africa Antibacterial (Drug) Resistance Sales Value Share by Country (%), 2025 VS 2032 Figure 52. USA Antibacterial (Drug) Resistance Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. USA Antibacterial (Drug) Resistance Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. USA Antibacterial (Drug) Resistance Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Canada Antibacterial (Drug) Resistance Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Canada Antibacterial (Drug) Resistance Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Canada Antibacterial (Drug) Resistance Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Mexico Antibacterial (Drug) Resistance Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Mexico Antibacterial (Drug) Resistance Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Mexico Antibacterial (Drug) Resistance Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Germany Antibacterial (Drug) Resistance Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Germany Antibacterial (Drug) Resistance Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Germany Antibacterial (Drug) Resistance Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. France Antibacterial (Drug) Resistance Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. France Antibacterial (Drug) Resistance Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. France Antibacterial (Drug) Resistance Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. U.K. Antibacterial (Drug) Resistance Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. U.K. Antibacterial (Drug) Resistance Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. U.K. Antibacterial (Drug) Resistance Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Italy Antibacterial (Drug) Resistance Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Italy Antibacterial (Drug) Resistance Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Italy Antibacterial (Drug) Resistance Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Spain Antibacterial (Drug) Resistance Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Spain Antibacterial (Drug) Resistance Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Spain Antibacterial (Drug) Resistance Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Russia Antibacterial (Drug) Resistance Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Russia Antibacterial (Drug) Resistance Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Russia Antibacterial (Drug) Resistance Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Netherlands Antibacterial (Drug) Resistance Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Netherlands Antibacterial (Drug) Resistance Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Netherlands Antibacterial (Drug) Resistance Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Nordic Countries Antibacterial (Drug) Resistance Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Nordic Countries Antibacterial (Drug) Resistance Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Nordic Countries Antibacterial (Drug) Resistance Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. China Antibacterial (Drug) Resistance Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. China Antibacterial (Drug) Resistance Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. China Antibacterial (Drug) Resistance Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Japan Antibacterial (Drug) Resistance Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Japan Antibacterial (Drug) Resistance Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Japan Antibacterial (Drug) Resistance Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. South Korea Antibacterial (Drug) Resistance Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. South Korea Antibacterial (Drug) Resistance Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. South Korea Antibacterial (Drug) Resistance Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. India Antibacterial (Drug) Resistance Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. India Antibacterial (Drug) Resistance Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. India Antibacterial (Drug) Resistance Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Australia Antibacterial (Drug) Resistance Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Australia Antibacterial (Drug) Resistance Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Australia Antibacterial (Drug) Resistance Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Southeast Asia Antibacterial (Drug) Resistance Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Southeast Asia Antibacterial (Drug) Resistance Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Southeast Asia Antibacterial (Drug) Resistance Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Brazil Antibacterial (Drug) Resistance Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Brazil Antibacterial (Drug) Resistance Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Brazil Antibacterial (Drug) Resistance Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Argentina Antibacterial (Drug) Resistance Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Argentina Antibacterial (Drug) Resistance Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Argentina Antibacterial (Drug) Resistance Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Chile Antibacterial (Drug) Resistance Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Chile Antibacterial (Drug) Resistance Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Chile Antibacterial (Drug) Resistance Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Colombia Antibacterial (Drug) Resistance Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Colombia Antibacterial (Drug) Resistance Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Colombia Antibacterial (Drug) Resistance Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Peru Antibacterial (Drug) Resistance Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Peru Antibacterial (Drug) Resistance Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Peru Antibacterial (Drug) Resistance Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Saudi Arabia Antibacterial (Drug) Resistance Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Saudi Arabia Antibacterial (Drug) Resistance Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Saudi Arabia Antibacterial (Drug) Resistance Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Israel Antibacterial (Drug) Resistance Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Israel Arabia Antibacterial (Drug) Resistance Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Israel Arabia Antibacterial (Drug) Resistance Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. UAE Antibacterial (Drug) Resistance Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. UAE Antibacterial (Drug) Resistance Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. UAE Antibacterial (Drug) Resistance Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Turkey Antibacterial (Drug) Resistance Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 128. Turkey Antibacterial (Drug) Resistance Sales Value Share by Type, 2025 VS 2032 & (%) Figure 129. Turkey Antibacterial (Drug) Resistance Sales Value Share by Application, 2025 VS 2032 & (%) Figure 130. Iran Antibacterial (Drug) Resistance Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 131. Iran Antibacterial (Drug) Resistance Sales Value Share by Type, 2025 VS 2032 & (%) Figure 132. Iran Antibacterial (Drug) Resistance Sales Value Share by Application, 2025 VS 2032 & (%) Figure 133. Egypt Antibacterial (Drug) Resistance Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 134. Egypt Antibacterial (Drug) Resistance Sales Value Share by Type, 2025 VS 2032 & (%) Figure 135. Egypt Antibacterial (Drug) Resistance Sales Value Share by Application, 2025 VS 2032 & (%) Figure 136. Antibacterial (Drug) Resistance Value Chain Figure 137. Manufacturing Cost Structure Figure 138. Antibacterial (Drug) Resistance Sales Mode & Process Figure 139. Direct Comparison with Distribution Share Figure 140. Distributors Profiles Figure 141. Years Considered Figure 142. Research Process Figure 143. Key Executives Interviewed

Scope & coverage.

Types
  • Ceftolozane-Tazobactam (Zerbaxa)
  • Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio)
  • Ceftaroline Fosamil (Teflaro/ Zinforo)
  • Ceftazidime-Avibactam (Avycaz/ Zavicefta)
  • Telavancin (Vibativ)
  • Tedizolid Phosphate (Sivextro)
  • PHASE III DRUGS
  • Dalbavancin (Dalvance/ Xydalba)
  • Oritavancin (Orbactiv/ Nuvocid)
  • Fidaxomicin (Dificid / Dificlir)
Applications
  • Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
  • Blood Stream Infections (BSI)
  • Community Acquired Bacterial Pneumonia (CABP)
  • Clostridium Difficile Infections (CDI)
  • Acute Bacterial Skin And Skin Structure Infections (ABSSSI)
  • Complicated Urinary Tract Infection (CUTI)
  • Complicated Intra-Abdominal Infections (CIAI)
Companies covered
  • Merck
  • Pfizer
  • GSK
  • VenatoRx Pharmaceuticals
  • PENDOPHARM
  • Osel
  • Novexel
  • NanoSafe Coatings
  • Nabriva Therapeutics
  • Morphochem
  • Microbecide
  • Melinta Therapeutics
  • Lyndra
  • Isis Pharmaceuticals
  • InterMune
  • Evolva Holding
  • Demuris
  • ContraFect
  • Cerexa
  • Aventis Pharma
  • Austell Laboratories
  • Assembly Biosciences
  • Arpida
  • ANTABIO
  • Allergan
  • Acino Holdings
  • Achaogen
  • Absynth Biologics
  • Abbott Laboratories
  • AAIPharma Services

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Antibacterial (Drug) Resistance Sales Value (2021-2032)
  4. 1.2.2 Global Antibacterial (Drug) Resistance Sales Volume (2021-2032)
  5. 1.2.3 Global Antibacterial (Drug) Resistance Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Antibacterial (Drug) Resistance Market Dynamics
  1. 2.1 Antibacterial (Drug) Resistance Industry Trends
  2. 2.2 Antibacterial (Drug) Resistance Industry Drivers
  3. 2.3 Antibacterial (Drug) Resistance Industry Opportunities and Challenges
  4. 2.4 Antibacterial (Drug) Resistance Industry Restraints
3 Antibacterial (Drug) Resistance Market by Company
  1. 3.1 Global Antibacterial (Drug) Resistance Company Revenue Ranking in 2025
  2. 3.2 Global Antibacterial (Drug) Resistance Revenue by Company (2021-2026)
  3. 3.3 Global Antibacterial (Drug) Resistance Sales Volume by Company (2021-2026)
  4. 3.4 Global Antibacterial (Drug) Resistance Average Price by Company (2021-2026)
  5. 3.5 Global Antibacterial (Drug) Resistance Company Ranking (2024-2026)
  6. 3.6 Global Antibacterial (Drug) Resistance Company Manufacturing Base and Headquarters
  7. 3.7 Global Antibacterial (Drug) Resistance Company Product Type and Application
  8. 3.8 Global Antibacterial (Drug) Resistance Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Antibacterial (Drug) Resistance Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Antibacterial (Drug) Resistance Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Antibacterial (Drug) Resistance Market by Type
  1. 4.1 Antibacterial (Drug) Resistance Type Introduction
  2. 4.1.1 Ceftolozane-Tazobactam (Zerbaxa)
  3. 4.1.2 Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio)
  4. 4.1.3 Ceftaroline Fosamil (Teflaro/ Zinforo)
  5. 4.1.4 Ceftazidime-Avibactam (Avycaz/ Zavicefta)
  6. 4.1.5 Telavancin (Vibativ)
  7. 4.1.6 Tedizolid Phosphate (Sivextro)
  8. 4.1.7 PHASE III DRUGS
  9. 4.1.8 Dalbavancin (Dalvance/ Xydalba)
  10. 4.1.9 Oritavancin (Orbactiv/ Nuvocid)
  11. 4.1.10 Fidaxomicin (Dificid / Dificlir)
  12. 4.2 Global Antibacterial (Drug) Resistance Sales Volume by Type
  13. 4.2.1 Global Antibacterial (Drug) Resistance Sales Volume by Type (2021 VS 2025 VS 2032)
  14. 4.2.2 Global Antibacterial (Drug) Resistance Sales Volume by Type (2021-2032)
  15. 4.2.3 Global Antibacterial (Drug) Resistance Sales Volume Share by Type (2021-2032)
  16. 4.3 Global Antibacterial (Drug) Resistance Sales Value by Type
  17. 4.3.1 Global Antibacterial (Drug) Resistance Sales Value by Type (2021 VS 2025 VS 2032)
  18. 4.3.2 Global Antibacterial (Drug) Resistance Sales Value by Type (2021-2032)
  19. 4.3.3 Global Antibacterial (Drug) Resistance Sales Value Share by Type (2021-2032)
5 Antibacterial (Drug) Resistance Market by Application
  1. 5.1 Antibacterial (Drug) Resistance Application Introduction
  2. 5.1.1 Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
  3. 5.1.2 Blood Stream Infections (BSI)
  4. 5.1.3 Community Acquired Bacterial Pneumonia (CABP)
  5. 5.1.4 Clostridium Difficile Infections (CDI)
  6. 5.1.5 Acute Bacterial Skin And Skin Structure Infections (ABSSSI)
  7. 5.1.6 Complicated Urinary Tract Infection (CUTI)
  8. 5.1.7 Complicated Intra-Abdominal Infections (CIAI)
  9. 5.2 Global Antibacterial (Drug) Resistance Sales Volume by Application
  10. 5.2.1 Global Antibacterial (Drug) Resistance Sales Volume by Application (2021 VS 2025 VS 2032)
  11. 5.2.2 Global Antibacterial (Drug) Resistance Sales Volume by Application (2021-2032)
  12. 5.2.3 Global Antibacterial (Drug) Resistance Sales Volume Share by Application (2021-2032)
  13. 5.3 Global Antibacterial (Drug) Resistance Sales Value by Application
  14. 5.3.1 Global Antibacterial (Drug) Resistance Sales Value by Application (2021 VS 2025 VS 2032)
  15. 5.3.2 Global Antibacterial (Drug) Resistance Sales Value by Application (2021-2032)
  16. 5.3.3 Global Antibacterial (Drug) Resistance Sales Value Share by Application (2021-2032)
6 Antibacterial (Drug) Resistance Regional Sales and Value Analysis
  1. 6.1 Global Antibacterial (Drug) Resistance Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Antibacterial (Drug) Resistance Sales by Region (2021-2032)
  3. 6.2.1 Global Antibacterial (Drug) Resistance Sales by Region: 2021-2026
  4. 6.2.2 Global Antibacterial (Drug) Resistance Sales by Region (2027-2032)
  5. 6.3 Global Antibacterial (Drug) Resistance Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Antibacterial (Drug) Resistance Sales Value by Region (2021-2032)
  7. 6.4.1 Global Antibacterial (Drug) Resistance Sales Value by Region: 2021-2026
  8. 6.4.2 Global Antibacterial (Drug) Resistance Sales Value by Region (2027-2032)
  9. 6.5 Global Antibacterial (Drug) Resistance Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Antibacterial (Drug) Resistance Sales Value (2021-2032)
  12. 6.6.2 North America Antibacterial (Drug) Resistance Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Antibacterial (Drug) Resistance Sales Value (2021-2032)
  15. 6.7.2 Europe Antibacterial (Drug) Resistance Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Antibacterial (Drug) Resistance Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Antibacterial (Drug) Resistance Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Antibacterial (Drug) Resistance Sales Value (2021-2032)
  21. 6.9.2 South America Antibacterial (Drug) Resistance Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Antibacterial (Drug) Resistance Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Antibacterial (Drug) Resistance Sales Value Share by Country, 2025 VS 2032
7 Antibacterial (Drug) Resistance Country-level Sales and Value Analysis
  1. 7.1 Global Antibacterial (Drug) Resistance Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Antibacterial (Drug) Resistance Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Antibacterial (Drug) Resistance Sales by Country (2021-2032)
  4. 7.3.1 Global Antibacterial (Drug) Resistance Sales by Country (2021-2026)
  5. 7.3.2 Global Antibacterial (Drug) Resistance Sales by Country (2027-2032)
  6. 7.4 Global Antibacterial (Drug) Resistance Sales Value by Country (2021-2032)
  7. 7.4.1 Global Antibacterial (Drug) Resistance Sales Value by Country (2021-2026)
  8. 7.4.2 Global Antibacterial (Drug) Resistance Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Antibacterial (Drug) Resistance Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Antibacterial (Drug) Resistance Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Antibacterial (Drug) Resistance Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Antibacterial (Drug) Resistance Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Antibacterial (Drug) Resistance Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Antibacterial (Drug) Resistance Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Antibacterial (Drug) Resistance Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Antibacterial (Drug) Resistance Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Antibacterial (Drug) Resistance Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Antibacterial (Drug) Resistance Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Antibacterial (Drug) Resistance Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Antibacterial (Drug) Resistance Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Antibacterial (Drug) Resistance Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Antibacterial (Drug) Resistance Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Antibacterial (Drug) Resistance Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Antibacterial (Drug) Resistance Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Antibacterial (Drug) Resistance Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Antibacterial (Drug) Resistance Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Antibacterial (Drug) Resistance Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Antibacterial (Drug) Resistance Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Antibacterial (Drug) Resistance Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Antibacterial (Drug) Resistance Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Antibacterial (Drug) Resistance Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Antibacterial (Drug) Resistance Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Antibacterial (Drug) Resistance Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Antibacterial (Drug) Resistance Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Antibacterial (Drug) Resistance Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Antibacterial (Drug) Resistance Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Antibacterial (Drug) Resistance Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Antibacterial (Drug) Resistance Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Antibacterial (Drug) Resistance Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Antibacterial (Drug) Resistance Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Antibacterial (Drug) Resistance Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Antibacterial (Drug) Resistance Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Antibacterial (Drug) Resistance Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Antibacterial (Drug) Resistance Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Antibacterial (Drug) Resistance Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Antibacterial (Drug) Resistance Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Antibacterial (Drug) Resistance Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Antibacterial (Drug) Resistance Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Antibacterial (Drug) Resistance Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Antibacterial (Drug) Resistance Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Antibacterial (Drug) Resistance Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Antibacterial (Drug) Resistance Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Antibacterial (Drug) Resistance Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Antibacterial (Drug) Resistance Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Antibacterial (Drug) Resistance Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Antibacterial (Drug) Resistance Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Antibacterial (Drug) Resistance Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Antibacterial (Drug) Resistance Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Antibacterial (Drug) Resistance Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Antibacterial (Drug) Resistance Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Antibacterial (Drug) Resistance Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Antibacterial (Drug) Resistance Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Antibacterial (Drug) Resistance Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Antibacterial (Drug) Resistance Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Antibacterial (Drug) Resistance Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Antibacterial (Drug) Resistance Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Antibacterial (Drug) Resistance Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Antibacterial (Drug) Resistance Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Antibacterial (Drug) Resistance Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Antibacterial (Drug) Resistance Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Antibacterial (Drug) Resistance Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Antibacterial (Drug) Resistance Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Antibacterial (Drug) Resistance Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Antibacterial (Drug) Resistance Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Antibacterial (Drug) Resistance Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Antibacterial (Drug) Resistance Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Antibacterial (Drug) Resistance Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Antibacterial (Drug) Resistance Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Antibacterial (Drug) Resistance Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Antibacterial (Drug) Resistance Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Antibacterial (Drug) Resistance Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Antibacterial (Drug) Resistance Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Antibacterial (Drug) Resistance Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Antibacterial (Drug) Resistance Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Antibacterial (Drug) Resistance Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Antibacterial (Drug) Resistance Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Antibacterial (Drug) Resistance Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Antibacterial (Drug) Resistance Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Antibacterial (Drug) Resistance Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Antibacterial (Drug) Resistance Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Antibacterial (Drug) Resistance Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Antibacterial (Drug) Resistance Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Merck
  2. 8.1.1 Merck Company Information
  3. 8.1.2 Merck Business Overview
  4. 8.1.3 Merck Antibacterial (Drug) Resistance Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Merck Antibacterial (Drug) Resistance Product Portfolio
  6. 8.1.5 Merck Recent Developments
  7. 8.2 Pfizer
  8. 8.2.1 Pfizer Company Information
  9. 8.2.2 Pfizer Business Overview
  10. 8.2.3 Pfizer Antibacterial (Drug) Resistance Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Pfizer Antibacterial (Drug) Resistance Product Portfolio
  12. 8.2.5 Pfizer Recent Developments
  13. 8.3 GSK
  14. 8.3.1 GSK Company Information
  15. 8.3.2 GSK Business Overview
  16. 8.3.3 GSK Antibacterial (Drug) Resistance Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 GSK Antibacterial (Drug) Resistance Product Portfolio
  18. 8.3.5 GSK Recent Developments
  19. 8.4 VenatoRx Pharmaceuticals
  20. 8.4.1 VenatoRx Pharmaceuticals Company Information
  21. 8.4.2 VenatoRx Pharmaceuticals Business Overview
  22. 8.4.3 VenatoRx Pharmaceuticals Antibacterial (Drug) Resistance Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 VenatoRx Pharmaceuticals Antibacterial (Drug) Resistance Product Portfolio
  24. 8.4.5 VenatoRx Pharmaceuticals Recent Developments
  25. 8.5 PENDOPHARM
  26. 8.5.1 PENDOPHARM Company Information
  27. 8.5.2 PENDOPHARM Business Overview
  28. 8.5.3 PENDOPHARM Antibacterial (Drug) Resistance Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 PENDOPHARM Antibacterial (Drug) Resistance Product Portfolio
  30. 8.5.5 PENDOPHARM Recent Developments
  31. 8.6 Osel
  32. 8.6.1 Osel Company Information
  33. 8.6.2 Osel Business Overview
  34. 8.6.3 Osel Antibacterial (Drug) Resistance Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Osel Antibacterial (Drug) Resistance Product Portfolio
  36. 8.6.5 Osel Recent Developments
  37. 8.7 Novexel
  38. 8.7.1 Novexel Company Information
  39. 8.7.2 Novexel Business Overview
  40. 8.7.3 Novexel Antibacterial (Drug) Resistance Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Novexel Antibacterial (Drug) Resistance Product Portfolio
  42. 8.7.5 Novexel Recent Developments
  43. 8.8 NanoSafe Coatings
  44. 8.8.1 NanoSafe Coatings Company Information
  45. 8.8.2 NanoSafe Coatings Business Overview
  46. 8.8.3 NanoSafe Coatings Antibacterial (Drug) Resistance Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 NanoSafe Coatings Antibacterial (Drug) Resistance Product Portfolio
  48. 8.8.5 NanoSafe Coatings Recent Developments
  49. 8.9 Nabriva Therapeutics
  50. 8.9.1 Nabriva Therapeutics Company Information
  51. 8.9.2 Nabriva Therapeutics Business Overview
  52. 8.9.3 Nabriva Therapeutics Antibacterial (Drug) Resistance Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Nabriva Therapeutics Antibacterial (Drug) Resistance Product Portfolio
  54. 8.9.5 Nabriva Therapeutics Recent Developments
  55. 8.10 Morphochem
  56. 8.10.1 Morphochem Company Information
  57. 8.10.2 Morphochem Business Overview
  58. 8.10.3 Morphochem Antibacterial (Drug) Resistance Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Morphochem Antibacterial (Drug) Resistance Product Portfolio
  60. 8.10.5 Morphochem Recent Developments
  61. 8.11 Microbecide
  62. 8.11.1 Microbecide Company Information
  63. 8.11.2 Microbecide Business Overview
  64. 8.11.3 Microbecide Antibacterial (Drug) Resistance Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Microbecide Antibacterial (Drug) Resistance Product Portfolio
  66. 8.11.5 Microbecide Recent Developments
  67. 8.12 Melinta Therapeutics
  68. 8.12.1 Melinta Therapeutics Company Information
  69. 8.12.2 Melinta Therapeutics Business Overview
  70. 8.12.3 Melinta Therapeutics Antibacterial (Drug) Resistance Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Melinta Therapeutics Antibacterial (Drug) Resistance Product Portfolio
  72. 8.12.5 Melinta Therapeutics Recent Developments
  73. 8.13 Lyndra
  74. 8.13.1 Lyndra Company Information
  75. 8.13.2 Lyndra Business Overview
  76. 8.13.3 Lyndra Antibacterial (Drug) Resistance Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Lyndra Antibacterial (Drug) Resistance Product Portfolio
  78. 8.13.5 Lyndra Recent Developments
  79. 8.14 Isis Pharmaceuticals
  80. 8.14.1 Isis Pharmaceuticals Company Information
  81. 8.14.2 Isis Pharmaceuticals Business Overview
  82. 8.14.3 Isis Pharmaceuticals Antibacterial (Drug) Resistance Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Isis Pharmaceuticals Antibacterial (Drug) Resistance Product Portfolio
  84. 8.14.5 Isis Pharmaceuticals Recent Developments
  85. 8.15 InterMune
  86. 8.15.1 InterMune Company Information
  87. 8.15.2 InterMune Business Overview
  88. 8.15.3 InterMune Antibacterial (Drug) Resistance Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 InterMune Antibacterial (Drug) Resistance Product Portfolio
  90. 8.15.5 InterMune Recent Developments
  91. 8.16 Evolva Holding
  92. 8.16.1 Evolva Holding Company Information
  93. 8.16.2 Evolva Holding Business Overview
  94. 8.16.3 Evolva Holding Antibacterial (Drug) Resistance Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Evolva Holding Antibacterial (Drug) Resistance Product Portfolio
  96. 8.16.5 Evolva Holding Recent Developments
  97. 8.17 Demuris
  98. 8.17.1 Demuris Company Information
  99. 8.17.2 Demuris Business Overview
  100. 8.17.3 Demuris Antibacterial (Drug) Resistance Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Demuris Antibacterial (Drug) Resistance Product Portfolio
  102. 8.17.5 Demuris Recent Developments
  103. 8.18 ContraFect
  104. 8.18.1 ContraFect Company Information
  105. 8.18.2 ContraFect Business Overview
  106. 8.18.3 ContraFect Antibacterial (Drug) Resistance Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 ContraFect Antibacterial (Drug) Resistance Product Portfolio
  108. 8.18.5 ContraFect Recent Developments
  109. 8.19 Cerexa
  110. 8.19.1 Cerexa Company Information
  111. 8.19.2 Cerexa Business Overview
  112. 8.19.3 Cerexa Antibacterial (Drug) Resistance Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Cerexa Antibacterial (Drug) Resistance Product Portfolio
  114. 8.19.5 Cerexa Recent Developments
  115. 8.20 Aventis Pharma
  116. 8.20.1 Aventis Pharma Company Information
  117. 8.20.2 Aventis Pharma Business Overview
  118. 8.20.3 Aventis Pharma Antibacterial (Drug) Resistance Sales, Value and Gross Margin (2021-2026)
  119. 8.20.4 Aventis Pharma Antibacterial (Drug) Resistance Product Portfolio
  120. 8.20.5 Aventis Pharma Recent Developments
  121. 8.21 Austell Laboratories
  122. 8.21.1 Austell Laboratories Company Information
  123. 8.21.2 Austell Laboratories Business Overview
  124. 8.21.3 Austell Laboratories Antibacterial (Drug) Resistance Sales, Value and Gross Margin (2021-2026)
  125. 8.21.4 Austell Laboratories Antibacterial (Drug) Resistance Product Portfolio
  126. 8.21.5 Austell Laboratories Recent Developments
  127. 8.22 Assembly Biosciences
  128. 8.22.1 Assembly Biosciences Company Information
  129. 8.22.2 Assembly Biosciences Business Overview
  130. 8.22.3 Assembly Biosciences Antibacterial (Drug) Resistance Sales, Value and Gross Margin (2021-2026)
  131. 8.22.4 Assembly Biosciences Antibacterial (Drug) Resistance Product Portfolio
  132. 8.22.5 Assembly Biosciences Recent Developments
  133. 8.23 Arpida
  134. 8.23.1 Arpida Company Information
  135. 8.23.2 Arpida Business Overview
  136. 8.23.3 Arpida Antibacterial (Drug) Resistance Sales, Value and Gross Margin (2021-2026)
  137. 8.23.4 Arpida Antibacterial (Drug) Resistance Product Portfolio
  138. 8.23.5 Arpida Recent Developments
  139. 8.24 ANTABIO
  140. 8.24.1 ANTABIO Company Information
  141. 8.24.2 ANTABIO Business Overview
  142. 8.24.3 ANTABIO Antibacterial (Drug) Resistance Sales, Value and Gross Margin (2021-2026)
  143. 8.24.4 ANTABIO Antibacterial (Drug) Resistance Product Portfolio
  144. 8.24.5 ANTABIO Recent Developments
  145. 8.25 Allergan
  146. 8.25.1 Allergan Company Information
  147. 8.25.2 Allergan Business Overview
  148. 8.25.3 Allergan Antibacterial (Drug) Resistance Sales, Value and Gross Margin (2021-2026)
  149. 8.25.4 Allergan Antibacterial (Drug) Resistance Product Portfolio
  150. 8.25.5 Allergan Recent Developments
  151. 8.26 Acino Holdings
  152. 8.26.1 Acino Holdings Company Information
  153. 8.26.2 Acino Holdings Business Overview
  154. 8.26.3 Acino Holdings Antibacterial (Drug) Resistance Sales, Value and Gross Margin (2021-2026)
  155. 8.26.4 Acino Holdings Antibacterial (Drug) Resistance Product Portfolio
  156. 8.26.5 Acino Holdings Recent Developments
  157. 8.27 Achaogen
  158. 8.27.1 Achaogen Company Information
  159. 8.27.2 Achaogen Business Overview
  160. 8.27.3 Achaogen Antibacterial (Drug) Resistance Sales, Value and Gross Margin (2021-2026)
  161. 8.27.4 Achaogen Antibacterial (Drug) Resistance Product Portfolio
  162. 8.27.5 Achaogen Recent Developments
  163. 8.28 Absynth Biologics
  164. 8.28.1 Absynth Biologics Company Information
  165. 8.28.2 Absynth Biologics Business Overview
  166. 8.28.3 Absynth Biologics Antibacterial (Drug) Resistance Sales, Value and Gross Margin (2021-2026)
  167. 8.28.4 Absynth Biologics Antibacterial (Drug) Resistance Product Portfolio
  168. 8.28.5 Absynth Biologics Recent Developments
  169. 8.29 Abbott Laboratories
  170. 8.29.1 Abbott Laboratories Company Information
  171. 8.29.2 Abbott Laboratories Business Overview
  172. 8.29.3 Abbott Laboratories Antibacterial (Drug) Resistance Sales, Value and Gross Margin (2021-2026)
  173. 8.29.4 Abbott Laboratories Antibacterial (Drug) Resistance Product Portfolio
  174. 8.29.5 Abbott Laboratories Recent Developments
  175. 8.30 AAIPharma Services
  176. 8.30.1 AAIPharma Services Company Information
  177. 8.30.2 AAIPharma Services Business Overview
  178. 8.30.3 AAIPharma Services Antibacterial (Drug) Resistance Sales, Value and Gross Margin (2021-2026)
  179. 8.30.4 AAIPharma Services Antibacterial (Drug) Resistance Product Portfolio
  180. 8.30.5 AAIPharma Services Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Antibacterial (Drug) Resistance Value Chain Analysis
  2. 9.1.1 Antibacterial (Drug) Resistance Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Antibacterial (Drug) Resistance Sales Mode & Process
  6. 9.2 Antibacterial (Drug) Resistance Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Antibacterial (Drug) Resistance Distributors
  9. 9.2.3 Antibacterial (Drug) Resistance Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst